文献速递哮喘

Rademikibart治疗中重度未控制哮喘的2b期随机临床试验

Rademikibart Treatment for Moderate-to-Severe Uncontrolled Asthma: A Phase 2B Randomized Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2025-01-01

这项全球2b期试验将322例中重度持续未控制哮喘成人按1:1:1随机分配至Rademikibart 150 mg、300 mg(每两周一次,首剂600 mg负荷)或安慰剂组,皮下给药24周。第12周支气管舒张剂前FEV1较安慰剂分别提高140 ml和189 ml,起效迅速并维持至24周,基线血嗜酸性粒细胞较高者改善更明显,安全性总体与安慰剂相似。

要点

  • Rademikibart 150 mg和300 mg组第12周FEV1较安慰剂分别提高140 ml和189 ml,均具统计学显著性。
  • FEV1改善第1周即出现并维持至24周,基线血嗜酸性粒细胞≥300/ml者第24周改善达420 ml(300 mg组)。
  • 24周内至少一次急性发作比例:150 mg组7.5%、300 mg组9.3%、安慰剂组16.7%。

核心结论

  • Rademikibart治疗24周可使中重度未控制哮喘患者肺功能与哮喘控制获得快速且持续的改善。

研究设计与样本

  • 全球2b期随机临床试验,322例中重度持续未控制哮喘成人按1:1:1随机分配至Rademikibart 150 mg、300 mg(每两周一次,首剂600 mg负荷)或安慰剂组,皮下给药24周。

主要发现

  • 第12周支气管舒张剂前FEV1较安慰剂的最小二乘均值变化:150 mg组140 ml(95%CI 44-236 ml,P=0.005),300 mg组189 ml(95%CI 92-286 ml,P<0.001)。
  • 支气管舒张剂前FEV1改善在第1周内快速出现并维持至第24周,基线血嗜酸性粒细胞较高者改善最大:≥300嗜酸性粒细胞/ml者第24周安慰剂校正FEV1改善在300 mg组为420 ml(95%CI 239-600 ml)。
  • FEV1占预计值百分比和哮喘控制问卷评分在24周内也观察到快速且持续的统计学显著改善。
  • 治疗中出现的不良事件总体与安慰剂相似,未观察到嗜酸性粒细胞增多;注射部位反应多为轻度,最常见(10-12%患者)为咳嗽、COVID-19和呼吸困难。

临床怎么用

  • 对于中重度未控制哮喘成人,Rademikibart每两周皮下给药可考虑作为改善肺功能与哮喘控制的候选方案。
  • 基线血嗜酸性粒细胞≥300/ml的患者可能从Rademikibart 300 mg治疗中获益更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Rademikibart (formerly CBP-201) is an IL-4Rα-targeting antibody. Objectives: We sought to evaluate rademikibart in adults with moderate-to-severe, persistent, uncontrolled asthma. Methods: In this global Phase 2b trial, 322 patients were randomized 1:1:1 to two rademikibart groups (150 mg or 300 mg every other week, after a 600-mg loading dose) or a placebo group; rademikibart or placebo was administered subcutaneously for 24 weeks. Measurements and Main Results: Prebronchodilator (trough) forced expiratory volume in 1 second (FEV1) at Week 12 (primary endpoint) improved with rademikibart at 150 mg and 300 mg: Least squares mean changes (95% confidence interval), above placebo, were 140 ml (44-236 ml; P = 0.005) and 189 ml (92-286 ml; P < 0.001), respectively. Prebronchodilator (trough) FEV1 improvements occurred rapidly during Week 1, were sustained through Week 24, and were greatest in patients with high baseline blood eosinophils (patients with ⩾300 eosinophils/ml experienced placebo-adjusted FEV1 improvement at Week 24 of 420 ml [95% confidence interval = 239-600 ml] in the 300-mg group). Rapid and sustained statistically significant improvements were also observed in percent predicted FEV1 and Asthma Control Questionnaire score across 24 weeks. Through Week 24, proportions of patients with one or more exacerbations were 7.5% (150 mg) and 9.3% (300 mg) versus 16.7% (placebo). Eighty-eight percent of patients completed treatment. Treatment-emergent adverse events were generally similar to placebo, and no eosinophilia was observed. Injection site reactions were mostly mild. The most common treatment-emergent adverse events (10-12% of patients) were cough, coronavirus disease (COVID-19), and dyspnea. Conclusions: Rapid and sustained improvements in lung function and asthma control were gained across 24 weeks of rademikibart therapy. Clinical trial registered with www.clinicaltrials.gov (NCT04773678).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Kerwin E, Yang T, Su N, et al. Rademikibart Treatment for Moderate-to-Severe Uncontrolled Asthma: A Phase 2B Randomized Clinical Trial. Am J Respir Crit Care Med. 2025. PMID: 39998473. doi:10.1164/rccm.202409-1708OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。